TURNING NOVEL DISCOVERIES INTO
INNOVATIVE HEALTH CARE SOLUTIONS.

KANE BIOTECH INC. is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and approximately 80% of all human bacterial infections involve biofilms. The healing of chronic wounds alone costs the United States health care system $20 billion per year.

Frequently Asked Questions

Kane Biotech - Winnipeg, MB

What exchange is Kane Biotech Inc. stock listed on and what is its symbol?

Kane Biotech is listed on the TSX Venture Exchange as KNE.

Can stock be purchased directly from the company?

Stock purchases for Kane Biotech must be made through your broker or dealer.

How many shares are outstanding?

As of June 7, 2011, there were 60,596,229 shares outstanding.

Who is the stock transfer agent?

Canadian Stock Transfer Company Inc.
600-333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1

When was Kane Biotech incorporated?

Kane Biotech Inc. was incorporated in Manitoba on May 17, 2001.

Where is Kane Biotech located?

Kane Biotech is headquartered in Winnipeg, Manitoba, Canada.

Who can I contact if I have questions or need more information?

Please email your request to ir@kanebiotech.com or call Investor Relations at 204.477.7592